Pulse Biosciences director granted 30,000 options

PULSE BIOSCIENCES, INC. director Richard van den Broek reported receiving two stock option grants.

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. director Richard van den Broek reported receiving two stock option grants. Each option is a right to buy Common Stock at an exercise price of $26.89 per share and expires on June 11, 2036.

One option covering 8,423 shares vests in equal monthly installments over one year starting on July 11, 2026, subject to his continued service. The other option covering 30,000 shares vests in equal quarterly installments over one year starting on September 5, 2026, also contingent on continued service. These are compensation-related awards, not open-market purchases or sales.

Insider Trade Summary

Grant/Award: 38,423 shares

Grant/Award 2 txns

Insider van den Broek Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	8,423	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,423 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
2. F2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pulse Biosciences (PLSE) director Richard van den Broek report in this Form 4?

He reported receiving two stock option grants as compensation. The options give him rights to buy Common Stock at a fixed price, subject to vesting over one year and continued service conditions.

How many Pulse Biosciences (PLSE) stock options were granted to the director?

He received one option for 8,423 underlying shares and another for 30,000 underlying shares. Each grant is separate, with its own vesting schedule tied to continued service with the company.

What is the exercise price and expiration date of the PLSE options granted?

Both stock option awards have an exercise price of $26.89 per share and expire on June 11, 2036. This fixed price defines what he must pay per share if he later exercises the options.

How do the new Pulse Biosciences (PLSE) options vest for the director?

The 8,423-share option vests in equal monthly installments over one year starting July 11, 2026. The 30,000-share option vests in equal quarterly installments over one year starting September 5, 2026, both requiring continued service.

Does this PLSE Form 4 show the director buying or selling shares on the market?

No, it shows compensation-related option grants, not open-market trades. The options are awards with a $26.89 exercise price and future vesting dates, rather than immediate purchases or sales of Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 09:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van den Broek Richard

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.89	06/11/2026		A		30,000		(1)	06/11/2036	Common Stock	30,000	$0	30,000	D
Stock Option (right to buy)	$26.89	06/11/2026		A		8,423		(2)	06/11/2036	Common Stock	8,423	$0	8,423	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.

2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

	/s/ Kenneth B. Stratton	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)